[1]
Johnson AJ, Tillett WS. The lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952; 95(5): 449-64.
[http://dx.doi.org/10.1084/jem.95.5.449] [PMID: 14927798]
[http://dx.doi.org/10.1084/jem.95.5.449] [PMID: 14927798]
[2]
Fletcher AP, Sherry S, Alkjaersig N, Smyrniotis FE, Jick S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest 1959; 38(7): 1111-9.
[http://dx.doi.org/10.1172/JCI103887] [PMID: 13664786]
[http://dx.doi.org/10.1172/JCI103887] [PMID: 13664786]
[3]
Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98(6): 1473-9.
[http://dx.doi.org/10.1378/chest.98.6.1473] [PMID: 2123152]
[http://dx.doi.org/10.1378/chest.98.6.1473] [PMID: 2123152]
[4]
Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353(9162): 1386-9.
[http://dx.doi.org/10.1016/S0140-6736(98)07534-5] [PMID: 10227218]
[http://dx.doi.org/10.1016/S0140-6736(98)07534-5] [PMID: 10227218]
[5]
Jerjes-Sanchez C, Ramírez-Rivera A, de Lourdes García M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: A randomized controlled trial. J Thromb Thrombolysis 1995; 2(3): 227-9.
[http://dx.doi.org/10.1007/BF01062714] [PMID: 10608028]
[http://dx.doi.org/10.1007/BF01062714] [PMID: 10608028]
[6]
Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347(15): 1143-50.
[http://dx.doi.org/10.1056/NEJMoa021274] [PMID: 12374874]
[http://dx.doi.org/10.1056/NEJMoa021274] [PMID: 12374874]
[7]
Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370(15): 1402-11.
[http://dx.doi.org/10.1056/NEJMoa1302097] [PMID: 24716681]
[http://dx.doi.org/10.1056/NEJMoa1302097] [PMID: 24716681]
[8]
Jimenez D, Martin-Saborido C, Muriel A, et al. Efficacy and safety outcomes of recanalisation procedures in patients with acute symptomatic pulmonary embolism: Systematic review and network meta-analysis. Thorax 2018; 73(5): 464-71.
[http://dx.doi.org/10.1136/thoraxjnl-2017-210040] [PMID: 29133351]
[http://dx.doi.org/10.1136/thoraxjnl-2017-210040] [PMID: 29133351]
[9]
Sadeghipour P, Jenab Y, Moosavi J, et al. Catheter-directed thrombolysis vs. anticoagulation in patients with acute intermediate-high–risk pulmonary embolism. JAMA Cardiol 2022; 7(12): 1189-97.
[http://dx.doi.org/10.1001/jamacardio.2022.3591] [PMID: 36260302]
[http://dx.doi.org/10.1001/jamacardio.2022.3591] [PMID: 36260302]
[10]
Bashir R, Foster M, Iskander A, et al. Pharmacomechanical catheter-directed thrombolysis with the bashir endovascular catheter for acute pulmonary embolism. JACC Cardiovasc Interv 2022; 15(23): 2427-36.
[http://dx.doi.org/10.1016/j.jcin.2022.09.011] [PMID: 36121244]
[http://dx.doi.org/10.1016/j.jcin.2022.09.011] [PMID: 36121244]
[11]
Kucher N, Boekstegers P, Müller OJ, et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation 2014; 129(4): 479-86.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005544] [PMID: 24226805]
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005544] [PMID: 24226805]
[12]
Avgerinos ED, Jaber W, Lacomis J, et al. Randomized trial comparing standard versus ultrasound-assisted thrombolysis for submassive pulmonary embolism. JACC Cardiovasc Interv 2021; 14(12): 1364-73.
[http://dx.doi.org/10.1016/j.jcin.2021.04.049] [PMID: 34167677]
[http://dx.doi.org/10.1016/j.jcin.2021.04.049] [PMID: 34167677]
[13]
Sista AK, Horowitz JM, Tapson VF, et al. Indigo aspiration system for treatment of pulmonary embolism. JACC Cardiovasc Interv 2021; 14(3): 319-29.
[http://dx.doi.org/10.1016/j.jcin.2020.09.053] [PMID: 33454291]
[http://dx.doi.org/10.1016/j.jcin.2020.09.053] [PMID: 33454291]
[14]
Toma C, Jaber WA, Weinberg MD, et al. Acute outcomes for the full US cohort of the FLASH mechanical thrombectomy registry in pulmonary embolism. EuroIntervention 2023; 18(14): 1201-12.
[http://dx.doi.org/10.4244/EIJ-D-22-00732] [PMID: 36349702]
[http://dx.doi.org/10.4244/EIJ-D-22-00732] [PMID: 36349702]
[15]
Horowitz JM, Jaber WA, Stegman B, et al. Mechanical thrombectomy for high-risk pulmonary embolism: Insights from the US cohort of the FLASH registry. JSCAI 2023; p. 101124.
[16]
Iannaccone M, Franchin L, Russo F, et al. Mortality across treatment strategies in intermediate-to-high risk pulmonary embolism in the modern era: A meta-analysis of observational studies and RCTs. Int J Cardiol 2023; 387: 131127.
[http://dx.doi.org/10.1016/j.ijcard.2023.131127] [PMID: 37355238]
[http://dx.doi.org/10.1016/j.ijcard.2023.131127] [PMID: 37355238]
Related Journals
Current Drug Safety
Current Medicinal Chemistry
Current Neuropharmacology
Current Pharmaceutical Analysis
Current Topics in Medicinal Chemistry
Current Vascular Pharmacology
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
CNS & Neurological Disorders - Drug Targets
Related Books
New Findings from Natural Substances
Mitochondrial DNA and the Immuno-inflammatory Response: New Frontiers to Control Specific Microbial Diseases
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research – Anti Allergy Agents
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Frontiers in Inflammation
